Johnson & Johnson (NYSE:JNJ) on Friday announced a Phase 3 trial win for its anti-inflammatory therapy Tremfya, highlighting ...

Johnson & Johnson's Phase 3b APEX study shows Tremfya reduces symptoms and structural damage in psoriatic arthritis patients ...

Secukinumab treatment reduces bone erosion volume and enhances partial healing of erosions in patients with psoriatic ...

Degenerative disc disease is common among young adults with PsA, with key risk factors including older age, male sex, diabetes, and inflammatory back pain.

While pharmacologic therapies remain central to managing PsO and PsA, non-pharmacologic interventions also play a crucial ...

Delays in diagnosing and treating psoriatic arthritis—a common inflammatory disorder affecting around 200,000 people in the U ...

A new cohort study published in Journal of American Medical Association suggests that biologics targeting IL-12, IL-23, and ...

A growing momentum for earlier treatment of psoriasis has the potential to improve outcomes with oral therapies and biologics ...

Psoriatic arthritis (PsA) is an immune-mediated condition, and people with PsA may be at a higher risk of developing many neurological conditions. Psoriatic arthritis (PsA) is an immune-mediated ...

Many people associate psoriatic arthritis (PsA) with itchy, scaly skin and joint pain, but excess fatigue is also a symptom for at least 50% of people with PsA. Fatigue from PsA might be mild ...

Johnson & Johnson announced that the Tremfya Phase 3b APEX study achieved both its primary endpoint of reducing signs and symptoms and its ...